TSE:EXE Extendicare (EXE) Stock Price, News & Analysis C$33.32 +0.19 (+0.57%) As of 05/15/2026 04:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesBuy This Stock About Extendicare Stock (TSE:EXE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Extendicare alerts:Sign Up Key Stats Today's RangeC$33.02▼C$33.8750-Day RangeC$25.40▼C$33.4452-Week RangeC$12.12▼C$35.62Volume519,219 shsAverage Volume324,240 shsMarket CapitalizationC$3.16 billionP/E Ratio24.52Dividend Yield1.52%Price TargetC$31.89Consensus RatingBuy Company Overview Extendicare Inc., operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services. Read More Extendicare Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreEXE MarketRank™: Extendicare scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingExtendicare has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Extendicare is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageExtendicare has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Extendicare's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Extendicare is 24.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.31.Price to Earnings Ratio vs. SectorThe P/E ratio of Extendicare is 24.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.07.Price to Book Value per Share RatioExtendicare has a P/B Ratio of 8.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for EXE. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldExtendicare pays a meaningful dividend of 1.53%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthExtendicare does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Extendicare is 37.24%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Extendicare's dividend. News and Social Media2.7 / 5News Sentiment0.33 News SentimentExtendicare has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Extendicare this week, compared to 1 article on an average week.Search Interest33 people have searched for EXE on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Extendicare insiders have not sold or bought any company stock.Percentage Held by Insiders13.92% of the stock of Extendicare is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20.30% of the stock of Extendicare is held by institutions.Read more about Extendicare's insider trading history. Receive EXE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Extendicare and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EXE Stock News HeadlinesExtendicare (TSE:EXE) Given New C$38.00 Price Target at BMO Capital MarketsMay 14 at 3:48 AM | americanbankingnews.comExtendicare (TSE:EXE) Given New C$34.00 Price Target at National Bank FinancialMay 13 at 3:33 AM | americanbankingnews.comThe gold strategy that works whether prices rise or fallFormer $900 million hedge fund manager Larry Benedict has developed a strategy he calls Gold Skimming - a way to target cash payouts from gold markets without buying a single ounce, mining stock, or ETF. With a reported 73% win rate across 19 trades and potential payouts of $2,975, $3,781, and $6,786 in a single day, Benedict has put together a free step-by-step walkthrough showing how it works whether gold climbs or pulls back.May 16 at 1:00 AM | Brownstone Research (Ad)Extendicare (TSE:EXE) Price Target Raised to C$39.00 at TDMay 12, 2026 | americanbankingnews.comExtendicare (TSE:EXE) Hits New 1-Year High - Should You Buy?May 10, 2026 | americanbankingnews.comExtendicare Inc. declares CAD 0.0441 dividendMay 9, 2026 | msn.comAssessing Extendicare (TSX:EXE) Valuation After A Powerful Share Price RunApril 30, 2026 | finance.yahoo.comCIBC, Extendicare, Great West at 52-Week Highs on NewsApril 28, 2026 | ca.finance.yahoo.comSee More Headlines EXE Stock Analysis - Frequently Asked Questions How have EXE shares performed this year? Extendicare's stock was trading at C$21.35 at the beginning of 2026. Since then, EXE shares have increased by 56.1% and is now trading at C$33.32. How were Extendicare's earnings last quarter? Extendicare Inc. (TSE:EXE) issued its earnings results on Thursday, May, 7th. The company reported $0.42 earnings per share for the quarter. The firm had revenue of $465.22 million for the quarter. Extendicare had a trailing twelve-month return on equity of 45.35% and a net margin of 6.99%. Read the conference call transcript. How do I buy shares of Extendicare? Shares of EXE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Extendicare own? Based on aggregate information from My MarketBeat watchlists, some other companies that Extendicare investors own include Enbridge (ENB), Enterprise Products Partners (EPD), Algonquin Power & Utilities (AQN), Bank of Nova Scotia (BNS), NVIDIA (NVDA), Pembina Pipeline (PPL) and BCE (BCE). Company Calendar Ex-Dividend for 5/15 Dividend4/30/2026Last Earnings5/07/2026Record date for 5/15 Dividend5/15/2026Dividend Payable5/15/2026Today5/16/2026Ex-Dividend for 6/15 Dividend5/29/2026Record date for 6/15 Dividend6/15/2026Dividend Payable6/15/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Medical Care Facilities Sub-IndustryN/A Current SymbolTSE:EXE CIKN/A Webwww.extendicare.com Phone905-470-4000FaxN/AEmployees23,000Year FoundedN/APrice Target and Rating Average Price Target for ExtendicareC$31.89 High Price TargetC$39.00 Low Price TargetC$22.50 Potential Upside/Downside-4.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)C$1.36 Trailing P/E Ratio24.52 Forward P/E Ratio54.31 P/E GrowthN/ANet IncomeC$65.46 million Net Margins6.99% Pretax MarginN/A Return on Equity45.35% Return on Assets7.16% Debt Debt-to-Equity Ratio82.55 Current Ratio1.44 Quick Ratio0.98 Sales & Book Value Annual SalesC$1.75 billion Price / Sales1.80 Cash FlowC$10.41 per share Price / Cash Flow3.20 Book ValueC$4.12 per share Price / Book8.08Miscellaneous Outstanding Shares94,822,000Free FloatN/AMarket CapC$3.16 billion OptionableNot Optionable Beta1.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (TSE:EXE) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Extendicare Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Extendicare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.